Abstract:Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen-host interactions, offer exciting and promising avenues for the development of new and improved vaccines.

Current and Future Challenges for Vaccine Development Especially COVID-19

The importance of vaccination

An Opportunities and Challenges in Vaccine Development

Current Progress in the Development of Prophylactic and Therapeutic Vaccines

Vaccines: present status and applications

Anti-Infectious Human Vaccination in Historical Perspective

The end of the beginning: vaccines for the next 25 years

Vaccines Through Centuries: Major Cornerstones of Global Health

From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health

Two centuries of vaccination: historical and conceptual approach and future perspectives

Live attenuated vaccines: Historical successes and current challenges

Progress in vaccine development for infectious diseases—a Keystone Symposia report

Maintaining Immunizations for Vaccine-Preventable Diseases in a Changing World

Advocate to vaccinate: moving away from the "politics" of vaccination

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Overcoming Vaccine Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines

[Vaccination against diarrheal diseases and typhoid fever. Current status and prospects]

Recent Developments in Prophylactic Immunization

[Vaccinations for emerging and re-emerging viral diseases]

Human health implications of emerging diseases and the current situation in India's vaccine industry

Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines